• Frank J Accurso, Fredrick Van Goor, Jiuhong Zha, Anne J Stone, Qunming Dong, Claudia L Ordonez, Steven M Rowe, John Paul Clancy, Michael W Konstan, Heather E Hoch, Sonya L Heltshe, Bonnie W Ramsey, Preston W Campbell, and Melissa A Ashlock.
• J. Cyst. Fibros. 2014 Mar 1;13(2):139-47.

BackgroundWe examined data from a Phase 2 trial {NCT00457821} of ivacaftor, a CFTR potentiator, in cystic fibrosis (CF) patients with aG551D mutation to evaluate standardized approaches to sweat chloride measurement and to explore the use of sweat chloride and nasal potential difference (NPD) to estimate CFTR activity.MethodsSweat chloride and NPD were secondary endpoints in this placebo-controlled, multicenter trial. Standardization of sweat collection, processing,and analysis was employed for the first time. Sweat chloride and chloride ion transport (NPD) were integrated into a model of CFTR activity.ResultsWithin-patient sweat chloride determinations showed sufficient precision to detect differences between dose-groups and assess ivacaftor treatment effects. Analysis of changes in sweat chloride and NPD demonstrated that patients treated with ivacaftor achieved CFTR activity equivalent to approximately 35%–40% of normal.ConclusionsSweat chloride is useful in multicenter trials as a biomarker of CFTR activity and to test the effect of CFTR potentiators.

36 keywords...

hide…